en · de · es · pt
cardarine-notes.peptides6823.com › Faq › Background And Regulatory History — Deep Dive

Background And Regulatory History — Deep Dive

By Editorial Desk · published 2026-04-23 · last reviewed 2026-05-09 · Faq

This is a working overview of Investigational drug, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-05-09. Anything still debated is marked as such rather than presented as settled.

Background and Regulatory History

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Regulatory Status and Detection Context

Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.

Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.

A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.

Cardarine at a glance

PropertyValueNotes
Common nameCardarineCommon internet and media name.
Research codeGW501516Also written GW-1516.
Drug classPPARδ agonistNot a selective androgen receptor modulator.
Development statusDiscontinuedClinical development halted after rodent cancer findings.
Regulatory statusProhibited in sportListed by WADA; not approved as medicine.

Background and Regulatory Status

Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.

Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.

Related pages on this site

Identity and Pharmacological Mechanism

Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.

The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.

Reference notes

In July 2015, Galloway endorsed Jeremy Corbyn's campaign in the Labour Party leadership election. He tweeted: "Congratulations to Jeremy Corbyn MP and good fortune in the labour leadership contest. If he wins it will change everything ..." He said that he would become a Labour Party member "pretty damn quick" if Corbyn was elected as leader. Less than a week after Corbyn became leader, a Labour spokeswoman told The Times: "George Galloway has not applied to rejoin the Labour party and he will not be receiving an invitation." Corbyn said in July 2015 that he was appalled at the tactics Galloway used while defending his seat against Naz Shah (Labour) during the general election. In December, Corbyn said that Galloway's readmission to the party was a decision not within his powers. In July 2016, Galloway endorsed Corbyn's campaign in the Labour Party leadership election. He said: "If Corbyn wins a big victory – and I think he will – then that should be, and it's important that it is, the final burial of Blair and Blairism." Following Ken Livingstone's much criticised comments in April 2016 concerning Adolf Hitler and Zionism, Galloway supported Livingstone's argument. Galloway disputed that Livingstone's comments were antisemitic. "The Israel lobby has just destroyed the Labour Party", he tweeted in May 2016. "It is an amazing achievement". The Respect Party "voluntarily deregistered" from the Electoral Commission on 18 August 2016.

Bukele denied the department's accusations, saying that the United States sought "absolute submission" from El Salvador rather than cooperation. The United States Department of Justice also accused Bukele's government of releasing gang leaders between 2019 and 2021 as a part of the negotiations, including Élmer "El Crook" Canales Rivera who was released in February 2021 despite having an active Interpol arrest warrant against him. In June 2025, ProPublica reported that U.S. extradition requests of MS-13 leaders considered potential witnesses had been blocked by Bukele's government. The outlet also reported that a U.S. multiagency law enforcement team, Joint Task Force Vulcan, had previously gathered evidence that United States Agency for International Development (USAID) funds to El Salvador had been laundered and used to pay key MS-13 leaders.

January 22 The United States leaves the World Health Organization. Trump's Executive Order 14253 is carried out, removing exhibits commemorating the history of slavery in the United States at the President's House. January 23 – The Office of Foreign Assets Control imposes sanctions on British-Palestinian activist Zaher Birawi, alleging that he has ties with Hamas. January 23–26 – A major winter storm and cold wave impact over 30 states and kill at least 85 people, with over 15 states of emergency being declared.

Sources: en.wikipedia.org

Reference notes

=== PMB === PMB (Probability Matrix from Blocks) of 2004 uses the additivity of evolutionary distances to improve on BLOSUM's analysis of the BLOCKS database. The up-to-date 2001 version of BLOCKS was used to generate a new set of BLOSUM matrices. The "observed substitution frequencies" found in these BLOSUM matrices are used to estimate actual substitution frequencies (with higher evolutionary distance, i.e. lower r, some later replacement can mask earlier replacements). PMB thus defines a true evolutionary model like PAM and JTT do. It is not a symmetric matrix.

=== 2012 === On February 23, 2012, NHK announced that with Shizuoka University they had developed an 8K sensor that can shoot video at 120 fps. In April 2012, Panasonic, in collaboration with NHK announced a 145 inches (370 cm) display (7680 × 4320 at 60 fps), which has 33.2 million 0.417 mm square pixels. In April 2012, the four major South Korean terrestrial broadcasters (KBS, MBC, SBS, and EBS) announced that in the future, they would begin test broadcasts of UHDTV on channel 66 in Seoul. At the time of the announcement, the UHDTV technical details had not yet been decided. LG Electronics and Samsung are also involved in UHDTV test broadcasts. In May 2012, NHK showed the world's first ultra-high-definition shoulder-mount camera. By reducing the size and weight of the camera, the portability had been improved, making it more maneuverable than previous prototypes, so it could be used in a wide variety of shooting situations. The single-chip sensor uses a Bayer color-filter array, where only one color component is acquired per pixel. Researchers at NHK also developed a high-quality up-converter, which estimates the other two color components to convert the output into full resolution video. Also in May 2012, NHK showed the ultra-high-definition imaging system it has developed in conjunction with Shizuoka University, which outputs 33.2-megapixel video at 120 fps with a color depth of 12 bits per component.

(2008) reported that the long hydrophobic Cys3-Cys4 loop is not required for rodlet assembly because its deletion does not affect the folding and physical properties of the monomeric protein, neither the morphology of the polymeric rodlet form. Instead, a region of the short Cys7-Cys8 loop, containing mainly uncharged polar residues, has been found to be critical for rodlet assembly. Characterization of EAS secondary elements involved in rodlet assembly have given insights into the mechanism behind class I hydrophobins self-assembly, but important structural differences with DewA, another class I hydrophobin, suggest that the mechanisms driving rodlet assembly vary among different types of hydrophobins. Like EAS, DewA also has a β-barrel core structure, but it differs significantly from it because of its considerable content of helical secondary elements. A unique feature of DewA is its capacity to exist as two types of conformers in solution, both able to form rodlet assemblies but at different rates. Despite these differences in structural and self-assembly mechanisms, both EAS and DewA form robust fibrillar monolayers, meaning that there must exist several pathways, protein sequences and tertiary conformations able to self-assemble into amphipathic monolayers. Further characterisation of both EAS and DewA and their rodlet self-assembly mechanisms will open up opportunities for rational design of hydrophobins with novel biotechnological applications.

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine a selective androgen receptor modulator?

No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.

Why did clinical development stop?

Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.

Is cardarine approved for medical use?

No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.

Is cardarine approved for any medical use?

No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.

Network